In this episode, we’ll delve into the medically and legally complex topic of cannabis. The legal landscape around marijuana has changed in the US in the past 15 years. Many of our patients now have legal access to products derived from cannabis, and they are turning to physicians for advice on whether these products can treat their neurologic conditions. Products derived from cannabis have been studied in a range of neurologic diseases. One product has shown modest efficacy (and is approved for use) in patients with Dravet Syndrome and Lennox-Gastaut Syndrome. The data for using cannabis-derived products in certain other neurologic conditions is less convincing and the use of these products remains controversial. How should we council our patients about this? Dr. Adeline Goss interviewed Dr. Michelle Cameron, associate professor at Oregon Health and Science University and Multiple Sclerosis (MS) specialist, on the use of medical use of cannabis and cannabinoids, with an emphasis in their use in treating the symptoms of MS. Dr. Cameron disclosed a consulting relationship with Greenwich Biosciences. Series 1, Episode 7